Intravenous use of mitomycin is indicated as monochemotherapy or in combined cytostatic chemotherapy in adults with: • advanced colorectal carcinoma • advanced gastric carcinoma • advanced and/or metastatic breast carcinoma • advanced oesophageal carcinoma • advanced cervical carcinoma • non-small-cell bronchial carcinoma • advanced pancreatic carcinoma • advanced tumours of the head and neck Intravesical use Mitomycin is indicated as intravesical administration for relapse prevention in adults with superficial urinary bladder carcinoma after transurethral resection.
Mitomycin medac 2mg,Mitomycin medac 2 mg
€450.50
Intravenous use Mitomycin is used in palliative tumour therapy.
